Home › Companies › CORVUS PHARMACEUTICALS INC. › 2024-2025
At CORVUS PHARMACEUTICALS INC.'s shareholder meeting held June 12, 2025, in the 2024-2025 proxy season, 58 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 167 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS — CORVUS PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CORVUS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 13, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and CORVUS PHARMACEUTICALS INC.’s Form 8-K, filed June 13, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 12, 2025: 4 items on CORVUS PHARMACEUTICALS INC.’s Form 8-K, filed June 13, 2025: 2 approved · 2 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore CORVUS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are CORVUS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 13, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Ian T. Clark | 28,853,180 | -- | -- | 10,420,373 | 14,121,947 | 73% | Not verified | — |
| Elect Director: Peter A. Thompson, M.D. | 38,832,016 | -- | -- | 441,537 | 14,121,947 | 99% | Not verified | — |
| 2. Ratification of Selection of Independent Registered Accounting Firm | 53,137,052 | 117,988 | 140,460 | -- | -- | 99.7% | Approved | — |
| Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers On a non-binding advisory basis, the Company's stockholders approved the compensation of the Company's named executive officers. | 37,113,137 | 2,096,601 | 63,815 | -- | 14,121,947 | 95% | Approved | — |
Source: CORVUS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 13, 2025 — read the filing on EDGAR.
Each item below shows how the 58 asset managers that disclosed a CORVUS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
73% Majority: yes · of votes cast
Description as filed by funds: To elect two Class III Directors with terms to expire at the 2028 annual meeting of stockholders: lan T. Clark
CORVUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Ian T. Clark”): 28,853,180 for, 10,420,373 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 73% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 231 for, 2,937,156 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 2,415,310 | Withhold |
| BlackRock | 0 | 0 | 0 | 327,165 | Withhold |
| American Century | 0 | 0 | 0 | 68,871 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 29,968 | Withhold |
| Fidelity | 0 | 0 | 0 | 26,311 | Withhold |
| FORUM FUNDS II | 0 | 0 | 0 | 19,642 | Withhold |
| ETFis Series Trust I | 0 | 0 | 0 | 15,202 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 11,855 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 6,600 | Withhold |
| Victory Capital | 0 | 0 | 0 | 5,074 | Withhold |
| Jackson National | 0 | 0 | 0 | 5,000 | Withhold |
| ProShares | 0 | 0 | 0 | 2,596 | Withhold |
| Equitable | 0 | 0 | 0 | 2,031 | Withhold |
| John Hancock | 0 | 0 | 0 | 1,228 | Withhold |
| State Street | 0 | 0 | 0 | 292 | Withhold |
| Advisors' Inner Circle Fund III | 231 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 11 | Withhold |
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect two Class III Directors with terms to expire at the 2028 annual meeting of stockholders: Peter A. Thompson, M.D.
CORVUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Peter A. Thompson, M.D.”): 38,832,016 for, 441,537 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 2,937,156 for, 231 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,415,310 | 0 | 0 | 0 | For |
| BlackRock | 327,165 | 0 | 0 | 0 | For |
| American Century | 68,871 | 0 | 0 | 0 | For |
| Charles Schwab | 29,968 | 0 | 0 | 0 | For |
| Fidelity | 26,311 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 19,642 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 15,202 | 0 | 0 | 0 | For |
| Goldman Sachs | 11,855 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 6,600 | 0 | 0 | 0 | For |
| Victory Capital | 5,074 | 0 | 0 | 0 | For |
| Jackson National | 5,000 | 0 | 0 | 0 | For |
| ProShares | 2,596 | 0 | 0 | 0 | For |
| Equitable | 2,031 | 0 | 0 | 0 | For |
| John Hancock | 1,228 | 0 | 0 | 0 | For |
| State Street | 292 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 231 | Withhold |
| BRIDGEWAY FUNDS INC | 11 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS
CORVUS PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers On a non-binding advisory basis, the Company's stockholders approved the compensation of the Company's named exe”): 37,113,137 for, 2,096,601 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers On a non-binding advisory basis, the Company's stockholders approved the compensation of the Company's named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,415,310 | 0 | 0 | 0 | For |
| BlackRock | 327,165 | 0 | 0 | 0 | For |
| American Century | 0 | 68,871 | 0 | 0 | Against |
| Charles Schwab | 29,968 | 0 | 0 | 0 | For |
| Fidelity | 26,311 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 19,642 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 15,202 | 0 | 0 | 0 | For |
| Goldman Sachs | 11,855 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 6,600 | 0 | 0 | 0 | For |
| Victory Capital | 5,074 | 0 | 0 | 0 | For |
| Jackson National | 5,000 | 0 | 0 | 0 | For |
| ProShares | 2,596 | 0 | 0 | 0 | For |
| Equitable | 2,031 | 0 | 0 | 0 | For |
| John Hancock | 1,228 | 0 | 0 | 0 | For |
| State Street | 292 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 231 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 11 | 0 | 0 | Against |
Fund voting reports, all 17 managers: 2,868,505 for, 68,882 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 6,943,654 | 0 | 0 | 0 | For |
| SAMLYN CAPITAL, LLC | 3,115,776 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 2,679,479 | 0 | 0 | 0 | For |
| Point72 | 2,451,005 | 0 | 0 | 0 | For |
| Vivo Capital, LLC | 2,234,566 | 0 | 0 | 0 | For |
| Foresite Capital Management VI LLC | 1,581,233 | 0 | 0 | 0 | For |
| DCF Advisers, LLC | 400,000 | 0 | 0 | 0 | For |
| BlackRock | 393,187 | 1,799 | 0 | 0 | For |
| Two Sigma | 189,877 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 162,000 | 0 | 0 | 0 | For |
| Citadel | 126,824 | 0 | 0 | 0 | For |
| OMERS ADMINISTRATION Corp | 124,072 | 0 | 0 | 0 | For |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 0 | 87,446 | 0 | 0 | Against |
| Wellington | 76,313 | 0 | 0 | 0 | For |
| American Century | 0 | 68,871 | 0 | 0 | Against |
| JACKSON SQUARE CAPITAL, LLC | 63,773 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 52,544 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 47,345 | 0 | 0 | 0 | For |
| Northern Trust | 46,896 | 0 | 0 | 0 | For |
| Renaissance | 35,870 | 0 | 0 | 0 | For |
| Charles Schwab | 29,968 | 0 | 0 | 0 | For |
| Graham Capital Management, L.P. | 23,290 | 0 | 0 | 0 | For |
| State Street | 22,863 | 0 | 0 | 0 | For |
| OPPENHEIMER & CO INC | 21,434 | 0 | 0 | 0 | For |
| COMMERCE BANK | 20,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 48 managers: 20,964,677 for, 164,899 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.7% Approved · of votes cast
Description as filed by funds: To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.
CORVUS PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Selection of Independent Registered Accounting Firm”): 53,137,052 for, 117,988 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 — Ratification of Selection of Independent Registered Accounting Firm The Company's stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 16 asset managers below reported 2,917,745 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,415,310 | 0 | 0 | 0 | For |
| BlackRock | 327,165 | 0 | 0 | 0 | For |
| American Century | 68,871 | 0 | 0 | 0 | For |
| Charles Schwab | 29,968 | 0 | 0 | 0 | For |
| Fidelity | 26,311 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 15,202 | 0 | 0 | 0 | For |
| Goldman Sachs | 11,855 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 6,600 | 0 | 0 | 0 | For |
| Victory Capital | 5,074 | 0 | 0 | 0 | For |
| Jackson National | 5,000 | 0 | 0 | 0 | For |
| ProShares | 2,596 | 0 | 0 | 0 | For |
| Equitable | 2,031 | 0 | 0 | 0 | For |
| John Hancock | 1,228 | 0 | 0 | 0 | For |
| State Street | 292 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 231 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 11 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 77,114,636 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.13% |
| 2 | BlackRock | 0.42% |
| 3 | American Century | 0.09% |
| 4 | Charles Schwab | 0.04% |
| 5 | Fidelity | 0.03% |
| 6 | FORUM FUNDS II | 0.03% |
| 7 | ETFis Series Trust I | 0.02% |
| 8 | Goldman Sachs | 0.02% |
| 9 | Blackstone Alternative Investment Funds | <0.01% |
| 10 | Victory Capital | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 9.00% |
| 2 | SAMLYN CAPITAL, LLC | 4.04% |
| 3 | RTW INVESTMENTS, LP | 3.47% |
| 4 | Point72 | 3.18% |
| 5 | Vivo Capital, LLC | 2.90% |
| 6 | Foresite Capital Management VI LLC | 2.05% |
| 7 | DCF Advisers, LLC | 0.52% |
| 8 | BlackRock | 0.51% |
| 9 | Two Sigma | 0.25% |
| 10 | PNC BANK, NATIONAL ASSOCIATION | 0.21% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| ORBIMED ADVISORS LLC | 11.16% | 13D |
| OrbiMed Private Investments V, LP | 9.00% | DEF14A |
| Peter A. Thompson, M.D. | 9.00% | DEF14A |
| Sirenia Capital Management LP | 8.86% | 13G |
| Samlyn Capital, LLC | 8.65% | DEF14A |
| Richard A. Miller | 7.89% | 13G |
| Elisha P. (Terry) Gould III | 4.25% | DEF14A |
| Adams Street Partners, LLC | 4.25% | 13D |
| Point72 Asset Management, L.P. | 3.93% | DEF14A |
| Point72 | 3.61% | 13F |
Percentages above are of 77,114,636 shares outstanding, as reported by CORVUS PHARMACEUTICALS INC. on its Form 10-Q dated May 8, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CORVUS PHARMACEUTICALS INC.’s 10-Q dated May 8, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
CORVUS PHARMACEUTICALS INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.
proxyvotesnow.com, “CORVUS PHARMACEUTICALS (CRVS) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/corvus-pharmaceuticals-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.